SBH
BPMC

Segall Bryant & Hamill’s Blueprint Medicines BPMC Stock Holding History

Segall Bryant & Hamill’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-135,909
Closed -$12M – 580
2025
Q1 		$12M Sell
135,909
-3,834
-3% -$374K 0.18% 174
2024
Q4 		$12.2M Sell
139,743
-1,879
-1% -$172K 0.17% 191
2024
Q3 		$13.1M Buy
141,622
+14,668
+12% +$1.46M 0.18% 185
2024
Q2 		$13.7M Buy
126,954
+3,457
+3% +$346K 0.24% 133
2024
Q1 		$11.7M Sell
123,497
-1,752
-1% -$150K 0.22% 160
2023
Q4 		$11.6M Buy
125,249
+30,099
+32% +$1.95M 0.22% 163
2023
Q3 		$4.78M Sell
95,150
-561
-0.6% -$30K 0.06% 328
2023
Q2 		$6.05M Buy
95,711
+531
+0.6% +$28.9K 0.06% 310
2023
Q1 		$4.28M Sell
95,180
-87,480
-48% -$3.94M 0.05% 359
2022
Q4 		$8M Sell
182,660
-25,971
-12% -$1.25M 0.09% 252
2022
Q3 		$13.7M Buy
208,631
+4,443
+2% +$285K 0.16% 160
2022
Q2 		$10.3M Buy
204,188
+28,752
+16% +$1.68M 0.12% 197
2022
Q1 		$11.2M Buy
175,436
+116,602
+198% +$8.37M 0.11% 202
2021
Q4 		$6.3M Buy
58,834
+15,498
+36% +$1.62M 0.06% 281
2021
Q3 		$4.45M Buy
43,336
+1,146
+3% +$107K 0.04% 354
2021
Q2 		$3.71M Buy
42,190
+2,557
+6% +$234K 0.04% 376
2021
Q1 		$3.85M Sell
39,633
-701
-2% -$70K 0.04% 380
2020
Q4 		$4.52M Sell
40,334
-749
-2% -$78.9K 0.05% 312
2020
Q3 		$3.81M Buy
41,083
+29,755
+263% +$2.29M 0.05% 295
2020
Q2 		$885K Buy
11,328
+340
+3% +$23K 0.01% 468
2020
Q1 		$642K Sell
10,988
-1,094
-9% -$70.4K 0.01% 536
2019
Q4 		$968K Buy
+12,082
New +$905K 0.02% 526

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Segall Bryant & Hamill's BPMC Position: Q2 2025 in Review

Segall Bryant & Hamill sold out of Blueprint Medicines (BPMC) in Q2 2025, closing a stake of 135,909 shares — an estimated $12M sold.

Segall Bryant & Hamill first reported a position in BPMC in Q4 2019 and held it in 22 quarters. The position peaked at $13.7M in Q3 2022. 354 funds tracked by Wall St. Rank hold BPMC as of Q2 2025.

  • Segall Bryant & Hamill reported no remaining Blueprint Medicines position as of Q2 2025 after selling out during the quarter.
  • Segall Bryant & Hamill sold 135,909 Blueprint Medicines shares in Q2 2025, an estimated $12M.
  • Segall Bryant & Hamill first reported a position in Blueprint Medicines in Q4 2019 and held it in 22 quarters.
  • Segall Bryant & Hamill's Blueprint Medicines position peaked at $13.7M in Q3 2022.
  • 354 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2025.

Based on Segall Bryant & Hamill's 13F filing for Q2 2025, filed 12 Aug 2025.